ADAndrew W. Duncan

Andrew W. Duncan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrew W. Duncan has a total of 102 co-authors. Here are the top co-authors by number of shared publications:

  • Frances Alencastro

    Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, USA

    9 shared publications
  • Evan R. Delgado

    Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA

    8 shared publications
  • Patrick D. Wilkinson

    Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, USA

    5 shared publications
  • Madeleine P. Leek

    Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, USA

    4 shared publications
  • Nairita Roy

    Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania; McGowan Institute for Regenerative Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania; Pittsburgh Liver Research Center, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania

    4 shared publications
  • Sierra R. Wilson

    Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, USA

    4 shared publications

Latest Publications

  • Open Access

    Diploid hepatocytes resist acetaminophen-induced liver injury through suppressed JNK signaling

    by Sierra R. Wilson, Evan R. Delgado, Frances Alencastro, Rosa L. Loewenstein, Madeleine P. Leek, Leah R. Peters, Kerollos Kamel, Patrick D. Wilkinson, Siddhi Jain, Joseph Locker, et al.

    The liver contains both diploid and polyploid hepatocytes, but their functional differences remain poorly understood. Emerging evidence suggests that each ploidy state contributes to regeneration in an injury-specific manner. We hypothesized that diploid hepatocytes promote healing after acetaminophen (APAP)-induced liver injury. To study ploidy populations in vivo, we utilized mice with a lifelong liver-specific knockout of E2f7 / E2f8 (LKO), which are enriched in diploid hepatocytes (> 70%) but otherwise normal. Control and LKO mice were treated with APAP (300 or 600 mg/kg), and injury was assessed over 0–96 h. Although both groups sustained injury, LKO mice showed improved survival, lower serum liver enzyme levels, and reduced necrosis and DNA fragmentation, indicating resistance to APAP-induced injury. To determine if resistance was due to E2f7/E2f8 loss or increased diploidy, we deleted E2f7/E2f8 in adult hepatocytes (HKO), a model that does not alter ploidy. Injury was similar between controls and HKO, ruling out gene deletion as the protective factor. Transcriptomic and protein analyses revealed minimal baseline differences; however, following APAP treatment, LKO livers exhibited reduced JNK activation and less mitochondrial injury. Finally, APAP-treated wild-type hepatocytes exhibited a shift toward lower ploidy, supporting the idea that diploid cells are more resistant to injury. These findings highlight hepatocyte ploidy as a key determinant of injury response and suggest a protective role for diploid hepatocytes in promoting liver resilience and regeneration.


  • Open Access

    Diploid Hepatocytes Resist Acetaminophen-Induced Liver Injury Through Suppressed JNK Signaling

    by Sierra R. Wilson, Evan R. Delgado, Frances Alencastro, Rosa L. Loewenstein, Madeleine P. Leek, Leah R. Peters, Kerollos Kamel, Patrick D. Wilkinson, Siddhi Jain, Joseph Locker, et al.

    Background & Aims: The liver contains both diploid and polyploid hepatocytes, but their functional differences remain poorly understood. Emerging evidence suggests that each ploidy state contributes to regeneration in an injury-specific manner. We hypothesized that diploid hepatocytes promote healing after acetaminophen (APAP)-induced liver injury. Approach & Results: To study ploidy populations in vivo , we utilized mice with a lifelong liver-specific knockout of E2f7 / E2f8 (LKO), which are enriched in diploid hepatocytes (>70%) but otherwise normal. Control and LKO mice were treated with APAP (300 or 600 mg/kg), and injury was assessed over 0-96 hours. Although both groups sustained injury, LKO mice showed improved survival, lower serum liver enzyme levels, and reduced necrosis and DNA fragmentation, indicating resistance to APAP-induced injury. To determine if resistance was due to E2f7/E2f8 loss or increased diploidy, we deleted E2f7/E2f8 in adult hepatocytes (HKO), a model that does not alter ploidy. Injury was similar between controls and HKO, ruling out gene deletion as the protective factor. Transcriptomic and protein analyses revealed minimal baseline differences; however, following APAP treatment, LKO livers exhibited reduced JNK activation and less mitochondrial injury. Finally, APAP-treated wild-type hepatocytes exhibited a shift toward lower ploidy, supporting the idea that diploid cells are more resistant to injury. Conclusions: Diploid hepatocytes resist APAP-induced liver injury through reduced JNK activation and mitochondrial damage. These findings highlight hepatocyte ploidy as a key determinant of injury response and suggest a protective role for diploid hepatocytes in promoting liver resilience and regeneration.

  • Open Access

    Constitutive Androstane Receptor induces Ribonucleotide Reductase-M2 expression and maintains hepatocyte ploidy in mice

    by Anjana Asokakumar, Bhoomika Mathur, Anthony Chau, Bea Cronologia, Frances Alencastro, Linda Wheeler, Christopher K. Mathews, David D. Moore, Andrew W. Duncan, Sayeepriyadarshini Anakk

    The nuclear receptor Constitutive Androstane Receptor (CAR/NR1i3) is known for regulating various liver functions, including detoxification, nutrient metabolism, and hepatocyte proliferation. While CAR activation has been previously linked to higher ploidy, the underlying mechanisms are not fully known. Here, we uncover a basal role for CAR in maintaining hepatocyte ploidy, such that CAR deletion increases the number of diploid (2c) hepatocytes with a concomitant reduction in tetraploid (4c) hepatocytes. We demonstrate that CAR controls the de novo dNTP synthesis by directly transactivating the Ribonucleotide Reductase-M2 ( RRM2 ) gene, which encodes the rate-limiting catalytic subunit of the enzyme, ribonucleotide reductase. Further, we find that the ligand-dependent CAR activation is sufficient to induce several genes involved in the de novo dNTP synthesis pathways, resulting in higher hepatic dATP and dTTP levels within the liver. Importantly, overexpressing RRM2 levels in CAR knockouts led to increased DNA synthesis and tetraploid (4c) hepatocytes compared to the control mice. Importantly, we demonstrate that CAR-mediated DNA synthesis in liver cells is dependent on catalytically active RRM2 function. Taken together, these findings reveal that the CAR-mediated RRM2 regulation contributes towards DNA synthesis and thereby maintains hepatocyte ploidy.


  • Pathological polyploidy and liver repair failure in RAD51-deficient mice

    by Andrew W. Duncan

    An abstract is unavailable. This article is available as a PDF only.


  • The Ploidy State as a Determinant of Hepatocyte Proliferation

    by Sierra R. Wilson, Andrew W. Duncan

    The liver's unique chromosomal variations, including polyploidy and aneuploidy, influence hepatocyte identity and function. Among the most well-studied mammalian polyploid cells, hepatocytes exhibit a dynamic interplay between diploid and polyploid states. The ploidy state is dynamic as hepatocytes move through the “ploidy conveyor,” undergoing ploidy reversal and re-polyploidization during proliferation. Both diploid and polyploid hepatocytes actively contribute to proliferation, with diploids demonstrating an enhanced proliferative capacity. This enhanced potential positions diploid hepatocytes as primary drivers of liver proliferation in multiple contexts, including homeostasis, regeneration and repopulation, compensatory proliferation following injury, and oncogenic proliferation. This review discusses the influence of ploidy variations on cellular activity. It presents a model for ploidy-associated hepatocyte proliferation, offering a deeper understanding of liver health and disease with the potential to uncover novel treatment approaches.


  • Dysregulation of Lipid and Glucose Homeostasis in Hepatocyte-Specific SLC25A34 Knockout Mice

    by Nairita Roy, Frances Alencastro, Bayley A. Roseman, Sierra R. Wilson, Evan R. Delgado, Meredith C. May, Bharat Bhushan, Fiona M. Bello, Michael J. Jurczak, Sruti Shiva, et al.


  • METTL3 Regulates Liver Homeostasis, Hepatocyte Ploidy, and Circadian Rhythm–Controlled Gene Expression in Mice

    by Juan M. Barajas, Cho-Hao Lin, Hui-Lung Sun, Frances Alencastro, Allen C. Zhu, Mona Aljuhani, Ladan Navari, Selen A. Yilmaz, Lianbo Yu, Kara Corps, et al.


  • Open Access

    Coordinated Cross-Talk Between the Myc and Mlx Networks in Liver Regeneration and Neoplasia

    by Huabo Wang, Jie Lu, Frances Alencastro, Alexander Roberts, Julia Fiedor, Patrick Carroll, Robert N. Eisenman, Sarangarajan Ranganathan, Michael Torbenson, Andrew W. Duncan, et al.

    Background & Aims: The c-Myc (Myc) bHLH-ZIP transcription factor is deregulated in most cancers. In association with Max, Myc controls target genes that supervise metabolism, ribosome biogenesis, translation and proliferation. This “Myc Network” cross-talks with the “Mlx Network”, which consists of the Myc-like proteins MondoA and ChREBP and Max-like Mlx. Together, this “Extended Myc Network” regulates both common and distinct genes targets. Here we studied the consequence of Myc and/or Mlx ablation in the liver, particularly those pertaining to hepatocyte proliferation, metabolism and spontaneous tumorigenesis. Methods: We examined the ability of hepatocytes lacking Mlx ( Mlx KO) or Myc+Mlx (double KO or DKO) to repopulate the liver over an extended period of time in a murine model of Type I tyrosinemia. We also compared this and other relevant behaviors, phenotypes and transcriptomes of the livers to those from previously characterized Myc KO, Chrebp KO and Myc KO x Chrebp KO mice. Results: Hepatocyte regenerative potential deteriorated as the Extended Myc Network was progressively dismantled. Genes and pathways dysregulated in Mlx KO and DKO hepatocytes included those pertaining to translation, mitochondrial function and non-alcoholic fatty liver disease (NAFLD). The Myc and Mlx Networks were shown to cross-talk, with the latter playing a disproportionate role in target gene regulation. All cohorts also developed NAFLD and molecular evidence of early steatohepatitis. Finally, Mlx KO and DKO mice displayed extensive hepatic adenomatosis. Conclusions: In addition to demonstrating cooperation between the Myc and Mlx Networks, this study revealed the latter to be more important in maintaining proliferative, metabolic and translational homeostasis, while concurrently serving as a suppressor of benign tumorigenesis. Synopsis: The Myc and Mlx Networks exhibit extensive cross-talk and regulate distinct but overlapping sets of transcriptional targets. The current work demonstrates the cooperation between these two Networks in supporting the regenerative capabilities of normal hepatocytes while also revealing that the Mlx Network serves as a suppressor of spontaneous hepatic adenomatosis


  • Scaffolding Protein IQGAP1 Is Dispensable, but Its Overexpression Promotes Hepatocellular Carcinoma via YAP1 Signaling

    by Evan R. Delgado, Hanna L. Erickson, Junyan Tao, Satdarshan P. Monga, Andrew W. Duncan, Sayeepriyadarshini Anakk

    IQ motif–containing GTPase-activating protein 1 (IQGAP1) is a ubiquitously expressed scaffolding protein that is overexpressed in a number of cancers, including liver cancer, and is associated with pro-tumorigenic processes such as cell proliferation, motility, and adhesion. IQGAP1 can integrate multiple signaling pathways and could be an effective anti-tumor target. Therefore, we examined the role for IQGAP1 in tumor initiation and promotion during liver carcinogenesis. We found that ectopic overexpression of IQGAP1 in the liver is not sufficient to initiate tumorigenesis. Moreover, the tumor burden and cell proliferation in the DEN-induced liver carcinogenesis model in Iqgap1-/-mice maybe driven by MET signaling. In contrast, IQGAP1 overexpression enhanced YAP activation and subsequent NUAK2 expression to accelerate and promote hepatocellular carcinoma (HCC) in a clinically relevant model expressing activated (S45Y) β-catenin and MET. Here, increasing IQGAP1 expression in vivo does not alter β-catenin or MET activation; instead, it promotes YAP activity. Overall, we demonstrate that although IQGAP1 expression is not required for HCC development, the gain of IQGAP1 function promotes the rapid onset and increased liver carcinogenesis. Our results show that an adequate amount of IQGAP1 scaffold is necessary to maintain the quiescent status of the liver.